Healthcare Industry News: TomoHD
News Release - February 2, 2010
Addenbrooke's Hospital Begins Treating Patients on Second TomoTherapy(R) Cancer Treatment SystemExpanded Capacity Provides Cambridge, England-Based Hospital With Ability to Treat More Patients With Advanced Image-Guided IMRT
MADISON, WI - (HSMN NewsFeed) - TomoTherapy Incorporated (NASDAQ:TOMO ), maker of advanced radiation therapy solutions for cancer care, announced today that Addenbrooke's Hospital, which is run by the Cambridge University Hospitals National Health Service (NHS) Foundation Trust, recently installed and began treating patients on its second TomoTherapy(R) radiation therapy system.
"The TomoTherapy platform has proven to be a highly efficient solution for daily image-guided radiotherapy with positional correction, and for the delivery of sophisticated treatment plans using high-quality intensity-modulated radiotherapy," said Neil Burnet, a consultant oncologist at Addenbrooke's. "With our second TomoTherapy system now in operation, we are able to offer this extraordinary treatment to more patients, expanding our ability to treat prostate cancer and more complex cases."
In October 2007, Addenbrooke's Hospital became the first NHS facility in England to install a TomoTherapy treatment system. The hospital selected the TomoTherapy solution because it offered highly precise, image-guided, intensity-modulated radiation therapy (IG-IMRT) in an integrated, easy-to-use package. This combination offers clinical flexibility not available with other radiation therapy systems, such as the ability to deliver more conformal treatments capable of addressing a wider array of patient needs. In addition to Cambridge, TomoTherapy(SM) treatments are currently available within the NHS in Newcastle and will be available shortly in Middlesbrough, Nottingham and London, as well as in the private Bupa Cromwell Hospital, London.
"TomoTherapy delivers on its promises," said Donna Routsis, lead research radiographer at Addenbrooke's. "Our experience validates that the TomoTherapy system provides superb quality treatment planning and delivery, as well as fast, easy, accurate and integrated, 3D volumetric image guidance. It has increased our confidence and enables us to approach challenging cases that were previously out of reach."
With its first TomoTherapy system, Addenbrooke's Hospital expanded its cancer care capabilities to treat more than 50 different types of cancers, including cranial and spinal tumors and pediatric cases. In addition, Addenbrooke's Hospital began accepting referrals from other facilities not equipped to handle complex tumors and neurological cases. The hospital treats, on average, 31 patients per day with its initial TomoTherapy unit. Clinicians improved efficiency of their TomoTherapy treatments with the introduction of a High Performance Couch in April 2009, which shaves minutes off treatment time by loading and unloading patients from the unit with a touch of a button. However, continued growing demand for TomoTherapy treatments resulted in Addenbrooke's decision to purchase its second system. The second system was used to treat its first patient in January 2010, and the hospital expects that the combination of the two units will enable them to treat more than 60 patients per day.
"Addenbrooke's experience truly showcases the versatility of the TomoTherapy system in treating a wide variety of clinical indications," said Frederick A. Robertson, M.D., TomoTherapy's president and CEO. "We are pleased that our system's ease of use has enabled Addenbrooke's to achieve tremendous efficiencies while expanding their capabilities to handle cases that range from the common and simple, to the rare and complex."
TomoTherapy technology is developed and manufactured by TomoTherapy Inc. and is supplied in the U.K. by Oncology Systems Limited, based in Shrewsbury, England.
About Oncology Systems Limited
Oncology Systems Limited is a privately owned company based in Shrewsbury, England. OSL is one of the largest suppliers of radiation therapy technology to the U.K. and Ireland. It distributes the TomoTherapy(R) Hi*Art(R) cancer treatment technology to the U.K.'s NHS and private radiotherapy facilities, and the Republic of Ireland.
About Addenbrooke's Hospital
Cambridge University Hospitals, one of the first Foundation Trusts, is a 1,000-bed teaching hospital, as well as one of the government's new biomedical research centres. It has a world-class research reputation, whilst also providing acute and specialist services for its local and regional population. Addenbrooke's radiotherapy service treats over 4,000 new patients per annum, with 59,000 treatment fractions delivered. In December 2008 Cambridge University Hospitals NHS Foundation Trust took the top prize -- Acute Organisation of the Year -- in the U.K.'s annual Health Service Journal Awards.
About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy(R) platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy's suite of solutions include its flagship Hi*Art(R) treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD(TM) treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile(TM) relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit http://www.tomotherapy.com/.
(C)2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi*Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.